OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment. Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004. METHODS: The median age at transplantation was 46 yr. Fifteen patients underwent the procedure as front-line therapy and four patients as salvage therapy. Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%). RESULTS: A 79% of patients achieved complete response, 5% partial response and 16% failed the procedure. After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%. Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL. CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT. Patients who are transplanted in a refractory disease state do not benefit from this procedure.
OBJECTIVES:Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment. Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004. METHODS: The median age at transplantation was 46 yr. Fifteen patients underwent the procedure as front-line therapy and four patients as salvage therapy. Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%). RESULTS: A 79% of patients achieved complete response, 5% partial response and 16% failed the procedure. After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%. Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL. CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT. Patients who are transplanted in a refractory disease state do not benefit from this procedure.
Authors: Andrei R Shustov; Theodore A Gooley; Brenda M Sandmaier; Judith Shizuru; Mohamed L Sorror; Firoozeh Sahebi; Peter McSweeney; Dietger Niederwieser; Benedetto Bruno; Rainer Storb; David G Maloney Journal: Br J Haematol Date: 2010-05-09 Impact factor: 6.998
Authors: Alex F Herrera; Allison Crosby-Thompson; Jonathan W Friedberg; Gregory A Abel; Myron S Czuczman; Leo I Gordon; Mark S Kaminski; Michael M Millenson; Auayporn P Nademanee; Joyce C Niland; Scott J Rodig; Maria A Rodriguez; Andrew D Zelenetz; Ann S LaCasce Journal: Cancer Date: 2014-04-04 Impact factor: 6.860
Authors: Narendranath Epperla; Kwang W Ahn; Carlos Litovich; Sairah Ahmed; Minoo Battiwalla; Jonathon B Cohen; Parastoo Dahi; Nosha Farhadfar; Umar Farooq; Cesar O Freytes; Nilanjan Ghosh; Bradley Haverkos; Alex Herrera; Mark Hertzberg; Gerhard Hildebrandt; David Inwards; Mohamed A Kharfan-Dabaja; Farhad Khimani; Hillard Lazarus; Aleksandr Lazaryan; Lazaros Lekakis; Hemant Murthy; Sunita Nathan; Taiga Nishihori; Attaphol Pawarode; Tim Prestidge; Praveen Ramakrishnan; Andrew R Rezvani; Rizwan Romee; Nirav N Shah; Ana Sureda; Timothy S Fenske; Mehdi Hamadani Journal: J Hematol Oncol Date: 2019-01-10 Impact factor: 17.388
Authors: Marta Rodríguez; Ruth Alonso-Alonso; Laura Tomás-Roca; Socorro M Rodríguez-Pinilla; Rebeca Manso-Alonso; Laura Cereceda; Jennifer Borregón; Teresa Villaescusa; Raúl Córdoba; Margarita Sánchez-Beato; Ismael Fernández-Miranda; Isabel Betancor; Carmen Bárcena; Juan F García; Manuela Mollejo; Mónica García-Cosio; Paloma Martin-Acosta; Fina Climent; Dolores Caballero; Lorena de la Fuente; Pablo Mínguez; Linda Kessler; Catherine Scholz; Antonio Gualberto; Rufino Mondéjar; Miguel A Piris Journal: Blood Adv Date: 2021-12-28